Provided By GlobeNewswire
Last update: May 13, 2024
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
NASDAQ:TSBX (6/13/2025, 2:19:33 PM)
0.3345
-0.02 (-6.22%)
Find more stocks in the Stock Screener
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.